Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Lugalbanda
    Junior Member
    • Oct 2016
    • 3

    #1

    Limma multifactor experiment design matrix

    Hi, so I am very confused as to how I can make a multifactor design for limma RNA differential expression. I've read other posts in different forums and none of the answers are very explicit (to me) as to how to build a multifactor design

    For examples, say I have p1N, p1T, p2N, and p2T, where p# is patient number and N/T is normal tumor.

    I can build a single factor design matrix like this:

    ------Normal------Tumor
    1 ------ 1 --------- 0
    2 ------ 0 --------- 1
    3 ------ 1 --------- 0
    4 ------ 0 --------- 1

    I am completely lost as to how I can build a numeric matrix with multiple factors, which in this case, the factors would be patient number and N/T.
  • dpryan
    Devon Ryan
    • Jul 2011
    • 3478

    #2
    Code:
    d = data.frame(patient=factor(c("p1", "p1", "p2", "p2", ...)),
                   condition=factor(c("N", "T", "N", "T", ...)))
    design = model.matrix(~patient + condition, d)
    N.B., I've likely made a typo somewhere, but that's the gist.

    Comment

    • Lugalbanda
      Junior Member
      • Oct 2016
      • 3

      #3
      Oh, I thought I had to manually build a numeric matrix for the design matrix. Thanks. I have a followup question. I understand that the intercept column that is resulted is used for pair wise comparison. My question is when to use:

      design = model.matrix(~0+patient + condition, d)
      as opposed to this
      design = model.matrix(~patient + condition, d)

      Ok I found this from another post:

      EDIT:
      "This [design = model.matrix(~0+patient + condition, d)] (a cell means model) simply computes the mean expression for each group, and then you have to make all contrasts explicitly. The [design = model.matrix(~patient + condition, d)] has an implicit contrast (everything is a comparison to control), so you have to make contrasts for some comparisons, but not for others."

      from https://support.bioconductor.org/p/57268/


      So is it safe to say this only matters if I am doing a contrast matrix comparison?
      Last edited by Lugalbanda; 10-18-2016, 09:35 AM.

      Comment

      • dpryan
        Devon Ryan
        • Jul 2011
        • 3478

        #4
        Correct, the "0+" is only needed if you want to specify contrasts, which aren't needed to answer your question.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
          by SEQadmin2



          CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

          Despite this, “CRISPR helped turn genome editing from a specialized technique into
          ...
          Yesterday, 11:01 AM
        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, Yesterday, 02:55 AM
        0 responses
        9 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-24-2026, 12:17 PM
        0 responses
        12 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-23-2026, 11:41 AM
        0 responses
        12 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-20-2026, 11:10 AM
        0 responses
        24 views
        0 reactions
        Last Post SEQadmin2  
        Working...